Neuroendocrine tumors are a rare form of cancer and are frequently of gastroenteropancreatic origin (GEP-NETs). GEP-NETs are often asymptomatic and diagnosed at a late stage with metastases and with limited possibility of surgical removal, thus with still high unmet medical need for treatment.
COMPETE and COMPOSE are two phase III clinical trials to evaluate Targeted Radionuclide Therapy with n.c.a. Lutetium-177-Edotreotide in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs).
Are you interested in learning more about neuroendocrine tumors, Targeted Radionuclide Therapy, or clinical trials investigating Targeted Radionuclide Therapy for GEP-NETs? Access more information, including participating clinical centers, under the following link.